202 related articles for article (PubMed ID: 35737088)
21. TIGIT Can Exert Immunosuppressive Effects on CD8+ T Cells by the CD155/TIGIT Signaling Pathway for Hepatocellular Carcinoma In Vitro.
Zhang C; Wang Y; Xun X; Wang S; Xiang X; Hu S; Cheng Q; Guo J; Li Z; Zhu J
J Immunother; 2020 Oct; 43(8):236-243. PubMed ID: 32804915
[TBL] [Abstract][Full Text] [Related]
22. Targeting TIGIT for cancer immunotherapy: recent advances and future directions.
Zhang P; Liu X; Gu Z; Jiang Z; Zhao S; Song Y; Yu J
Biomark Res; 2024 Jan; 12(1):7. PubMed ID: 38229100
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.
Dancsok AR; Gao D; Lee AF; Steigen SE; Blay JY; Thomas DM; Maki RG; Nielsen TO; Demicco EG
Oncoimmunology; 2020; 9(1):1747340. PubMed ID: 32313727
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance of Signal Regulatory Protein Alpha (SIRPα) Expression in Hepatocellular Carcinoma.
Tomiyama T; Itoh S; Iseda N; Toshida K; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Harada N; Liu YC; Ozaki D; Kohashi K; Oda Y; Mori M; Yoshizumi T
Ann Surg Oncol; 2023 Jun; 30(6):3378-3389. PubMed ID: 36641515
[TBL] [Abstract][Full Text] [Related]
25. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
26. Implications of PD-1, Tim-3, and TIGIT Expression for Cancer Immunity and Pancreatic Cancer Prognosis.
Nakayama C; Tanoue K; Idichi T; Shimomura H; Kita Y; Hozaka Y; Shinden Y; Matsushita D; Nakajo A; Arigami T; Mataki Y; Kurahara H; Ohtsuka T
Anticancer Res; 2022 Jul; 42(7):3373-3380. PubMed ID: 35790289
[TBL] [Abstract][Full Text] [Related]
27. CD155 mutation (Ala67Thr) increases the binding affinity for and the signaling via an inhibitory immunoreceptor TIGIT.
Matsuo T; Iguchi-Manaka A; Shibuya A; Shibuya K
Cancer Sci; 2022 Nov; 113(11):4001-4004. PubMed ID: 35947095
[TBL] [Abstract][Full Text] [Related]
28. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer.
Heiduk M; Klimova A; Reiche C; Digomann D; Beer C; Aust DE; Distler M; Weitz J; Seifert AM; Seifert L
Clin Cancer Res; 2023 Jul; 29(14):2638-2650. PubMed ID: 37140899
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRPα infiltration after denosumab treatment.
Toda Y; Kohashi K; Yamamoto H; Ishihara S; Ito Y; Susuki Y; Kawaguchi K; Kiyozawa D; Takamatsu D; Kinoshita I; Yamada Y; Maehara J; Kimura A; Tamiya S; Taguchi K; Matsunobu T; Matsumoto Y; Nakashima Y; Mawatari M; Oda Y
Sci Rep; 2021 Jul; 11(1):14821. PubMed ID: 34285260
[TBL] [Abstract][Full Text] [Related]
30. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
[TBL] [Abstract][Full Text] [Related]
31. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
32. Development of Anti-human T Cell Immunoreceptor with Ig and ITIM Domains (TIGIT) Monoclonal Antibodies for Flow Cytometry.
Takei J; Asano T; Nanamiya R; Nakamura T; Yanaka M; Hosono H; Tanaka T; Sano M; Kaneko MK; Harada H; Kato Y
Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):71-75. PubMed ID: 33900817
[TBL] [Abstract][Full Text] [Related]
33. Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy.
Mori M; Kanayama M; Kuwata T; Manabe T; Nemoto Y; Nishizawa N; Oyama R; Matsumiya H; Nabe Y; Taira A; Takenaka M; Yoneda K; Kuroda K; Tanaka F
Sci Rep; 2023 Feb; 13(1):3270. PubMed ID: 36841853
[TBL] [Abstract][Full Text] [Related]
34. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
35. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
36. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
37. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of the tumor immune microenvironment in synovial sarcoma.
Oike N; Kawashima H; Ogose A; Hotta T; Hatano H; Ariizumi T; Sasaki T; Yamagishi T; Umezu H; Endo N
Cancer Sci; 2018 Oct; 109(10):3043-3054. PubMed ID: 30133055
[TBL] [Abstract][Full Text] [Related]
39. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M; Richard C; Limagne E; Boidot R; Morgand V; Bertaut A; Derangere V; Laurent PA; Thibaudin M; Fumet JD; Crehange G; Ghiringhelli F; Mirjolet C
J Immunother Cancer; 2019 Jun; 7(1):160. PubMed ID: 31238970
[TBL] [Abstract][Full Text] [Related]
40. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.
Zhu L; Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Palmisiano ND; Wang M; Jia B; Bayerl M; Schell TD; Hohl RJ; Zeng H; Zheng H
J Hematol Oncol; 2017 Jun; 10(1):124. PubMed ID: 28629373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
